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Adrenomedullin is a vasodilatatory peptide, important during the inflammation process and also able to regulate 
blood-brain barrier function. Adrenomedullin and its receptors have been shown to be glucocorticoid-dependent in 
many cell types, including primary T cells and the major cellular components of the blood-brain barrier. Considering 
that the immunosuppressant, glucocorticoids are also well-known to regulate inflammation and blood-brain barrier 
properties, in this research highlight we review the evidence for glucocorticoid modulation of adrenomedullin 
secretion and adrenomedullin receptor expression at the glial/endothelial interface during physiological and 
inflammatory conditions. This view would offer a platform for consideration of new therapeutic options aiming to 
restore or maintain the blood brain barrier. 
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Adrenomedullin (AM), a recently-discovered 
vasodilatory peptide, circulates in the plasma and is 
produced by a variety of cells [1]. AM effects are mediated 
through a G-protein coupled receptor, calcitonin receptor-
like receptor (CLR) associated with receptor-activity 
modifying protein (RAMP) 2 or 3 [2]. AM-AM receptor 
binding can increase intracellular cAMP levels [3, 4] and/or 
cause calcium mobilization [4, 5]. Importantly, considering 
that AM is highly produced by cerebral endothelial cells 
(CEC), this peptide concentration is greater in the brain 
than in the peripheral vasculature [6]. Interestingly, 
astrocytes seem to have a key role in blood-brain barrier 
(BBB) AM production, as when endothelial cells are co-
cultured with astroglia or astrocyte-conditioned media, 
they increase their AM production [6]  suggesting that 
AM up-regulation may depend on astrocyte soluble 
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factors. Indeed, AM has also been shown to be important 
in the regulation of BBB properties such as increased 
trans-endothelial electrical resistance and decreased 
endothelial permeability [7]. Exogenous application of AM 
does activate adenylate cyclase, therefore increase cAMP 
levels in CEC [7]. Since cAMP is a key second messenger 
in maintaining BBB functions [8], this suggests a direct role 
for AM as an autocrine and/or paracrine regulator of BBB. 
Furthermore, a tightening of intercellular junctions and 
changes in tight junction principal protein expression (i.e. 
occludin, claudin and ZO) were observed in response to 
treatment with AM [7], and is supported by further studies 
demonstrating an increase in claudin-5 after AM exposure 
in a dose-dependent manner [9]. Finally, AM can activate 
P-glycoprotein indicating a role for this peptide in the 
regulation of specific BBB efflux transporter systems [7].  
AM and its receptors have been shown to be 
glucocorticoid (GC)-dependent in cultured rat ventricular 
myocytes [10], human vascular endothelial cells [11] and 
T98G human glioblastoma cells [12]. Both AM secretion 
and mRNA levels were elevated in a dose-dependent and 
time-dependent manner [10, 11] following dexamethasone 
treatment. Furthermore, previous investigations have 
reported that GCs could augment AM concentration and 
expression dose-dependently also in vivo [13].Interestingly, 
GCs are not alone in that, other hormone group could 
regulate AM secretion and receptors expression [14,15].  
In opposition to its role in maintaining BBB function, 
AM is also an important mediator of inflammation and its 
concentration seems to increase under inflammatory 
conditions [16-18]. Indeed, endothelial cells and vascular 
smooth muscle cells display augmented AM production 
following exposure to IL-1, TNF-α and LPS [19]. Similar 
data were obtained with astrocytes: when cells were 
treated with TNF-α, IL-1 and INF-γ, their production of 
AM was significantly increased [20]. In vivo experiments 
reported that the peptide could reduce inflammation levels 
in experimental arthritis where it was able to ameliorate 
not only the incidence but also severity of the disease [21] . 
These anti-inflammatory properties of AM were also 
observed in two different models of sepsis where 
treatments with AM could significantly diminish the levels 
of immuno-inflammatory mediators [22]. Interestingly, AM 
was observed concomitant with the development of 
neuroinflammatory lesions in a rat paradigm of multiple 
sclerosis [23].  Considering that GCs are the best-known 
immunosuppressant, exerting an important role during the 
inflammatory process [24], our group investigated GC-
dependency for AM and its receptor in primary T cells 
before and after stimulation [25]. In these cells AM receptor 
presentation is GC-sensitive, which was highly dependent 
on the stimulation state. As a result, the interaction of these 
two molecules seems important during inflammation, as 
well as under physiological conditions.   
It is well-known that the BBB is hormonally regulated 
as its features are also influenced by circulating peripheral 
hormones [26]. Indeed, GCs were able to restore BBB 
properties when disrupted as well as maintain its 
physiological conditions [24, 27, 28]. Since both endothelial 
cells and astrocytes are fundamental components of the 
functional BBB [29], and as both GCs and AM have been 
shown to play a relevant role in regulating BBB 
characteristics [7, 30], our further studies aimed to identify 
whether these two molecules could interact in these cell 
types [31]. GCs were able to alter RAMP2 expression in 
endothelial-like cells, hence regulate AM-sensitivity, 
while they mainly influenced AM secretion in astrocytes. 
Our results have implications not only for the BBB 
characteristics under physiological conditions but also but 
also during inflammatory responses. More specifically, 
both AM [7] and GCs [30] have been closely related with 
acute pathological states, beside their ability to restore the 
BBB characteristics during neuro-inflammation. 
Moreover, AM was able to protect the BBB against 
oxidative stress, as during hypoxia addition of AM 
attenuated CEC permeability and preserved cell viability 
in an in vitro BBB model [32].  
In conclusion, our studies have shown that the ability of 
GCs to influence AM secretion and AM sensitivity 
intimately depended on the cell type. This is in line with 
our previous observations in T cells, where GCs could alter 
AM receptor expression depending on the stimulation 
state. Taken together, these data strongly suggest that 
GC’s modulation of AM secretion and AM sensitivity is a 
key feature for steroids during inflammation as well as 
under physiological conditions. As a result, AM has the 
potential for consideration as a novel therapeutic target in 
pathologies where there is a neuroinflammatory 
component.  
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